Eplerenone works. Does it matter how

activity, may be detectable in patients treated with eplerenone, as compared with placebo, during the first month; and whether these effects were associated with the drug’s beneficial action on long-term cardiovascular outcomes. At 1 month, the group treated with epler enone showed a significant – although hardly clinically relevant – reduction in estimated plasma volume. This difference was no longer significant at the third month, despite the per-protocol uptitration to a higher dose of 50 mg daily of eplerenone.